Brief: Aerovate Therapeutics Publishes Results Of Phase 1 Study Evaluating AV-101 For The Treatment Of Pulmonary Arterial Hypertension In ERJ Open Research

Jade Biosciences

17/11/2022 12:54

Nov 17 (Reuters) - Aerovate Therapeutics Inc  AVTE.O :
    * AEROVATE THERAPEUTICS PUBLISHES RESULTS OF PHASE 1 STUDY
EVALUATING AV-101 FOR THE TREATMENT OF PULMONARY ARTERIAL
HYPERTENSION IN ERJ OPEN RESEARCH
    * AEROVATE THERAPEUTICS INC - NO SERIOUS TREATMENT-EMERGENT
ADVERSE EVENTS (TEAES) WERE REPORTED IN EITHER SAD OR MAD
COHORTS
    * AEROVATE THERAPEUTICS INC - DEVELOPMENT OF IMATINIB FOR
PAH WAS
DISCONTINUED
    * AEROVATE THERAPEUTICS INC - AV-101 WAS GENERALLY WELL
TOLERATED
    * AEROVATE THERAPEUTICS INC - ENROLLMENT IS ONGOING AND
TOPLINE
DATA ARE EXPECTED FROM PHASE 2B PORTION OF TRIAL IN Q4 OF 2023
OR Q1 OF 2024

Source text for Eikon:  ID:nGNXNszYL 
Further company coverage:  AVTE.O